हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Ajin Park
Cervical cancer, primarily caused by persistent high-risk human papillomavirus (HPV) infection, is a significant global health concern affecting women worldwide. This article delves into the intricate relationship between genetics and cervical cancer, exploring the role of genetic factors in susceptibility, tumor development, and personalized treatment strategies. The genetic landscape of cervical cancer encompasses host genetic variations that influence susceptibility to HPV infection, alterations in tumor suppressor genes and oncogenic pathways that drive abnormal cell growth, and epigenetic modifications that silence critical genes. Moreover, hereditary factors and rare genetic syndromes contribute to a subset of cases. The emergence of precision medicine has paved the way for personalized treatment approaches that target genetic alterations in cervical cancer cells, thereby improving treatment efficacy. Although genetic testing is not the primary method for cervical cancer screening, it holds potential for identifying individuals at elevated risk due to genetic predisposition. Regular screening, HPV vaccination, and genetic counseling collectively contribute to early detection, prevention, and informed decision-making. As we unravel the genetic tapestry of cervical cancer, we gain profound insights into its complexities, paving the way for a future with improved management and reduced disease burden.